438 related articles for article (PubMed ID: 31796066)
21. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
[TBL] [Abstract][Full Text] [Related]
23. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
24. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014
[TBL] [Abstract][Full Text] [Related]
25. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
[TBL] [Abstract][Full Text] [Related]
27. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
28. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
[TBL] [Abstract][Full Text] [Related]
29. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
30. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.
Mackay TM; Smits FJ; Roos D; Bonsing BA; Bosscha K; Busch OR; Creemers GJ; van Dam RM; van Eijck CHJ; Gerhards MF; de Groot JWB; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Homs MYV; Kazemier G; Liem MSL; de Meijer VE; Molenaar IQ; Nieuwenhuijs VB; van Santvoort HC; van der Schelling GP; Stommel MWJ; Ten Tije AJ; de Vos-Geelen J; Wit F; Wilmink JW; van Laarhoven HWM; Besselink MG;
HPB (Oxford); 2020 Feb; 22(2):233-240. PubMed ID: 31439478
[TBL] [Abstract][Full Text] [Related]
31. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
32. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
[TBL] [Abstract][Full Text] [Related]
34. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.
Cloyd JM; Katz MH; Prakash L; Varadhachary GR; Wolff RA; Shroff RT; Javle M; Fogelman D; Overman M; Crane CH; Koay EJ; Das P; Krishnan S; Minsky BD; Lee JH; Bhutani MS; Weston B; Ross W; Bhosale P; Tamm EP; Wang H; Maitra A; Kim MP; Aloia TA; Vauthey JN; Fleming JB; Abbruzzese JL; Pisters PW; Evans DB; Lee JE
J Gastrointest Surg; 2017 Jan; 21(1):164-174. PubMed ID: 27778257
[TBL] [Abstract][Full Text] [Related]
35. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients.
Sho M; Murakami Y; Motoi F; Satoi S; Matsumoto I; Kawai M; Honda G; Uemura K; Yanagimoto H; Kurata M; Fukumoto T; Akahori T; Kinoshita S; Nagai M; Nishiwada S; Unno M; Yamaue H; Nakajima Y
J Gastroenterol; 2015 Jun; 50(6):694-702. PubMed ID: 25341657
[TBL] [Abstract][Full Text] [Related]
36. DUPAN-2 as a Risk Factor of Early Recurrence After Curative Pancreatectomy for Patients With Pancreatic Ductal Adenocarcinoma.
Sasaki A; Sakata K; Nakano K; Tsutsumi S; Fujishima H; Futsukaichi T; Terashi T; Ikebe M; Bandoh T; Utsunomiya T
Pancreas; 2023 Feb; 52(2):e110-e114. PubMed ID: 37523601
[TBL] [Abstract][Full Text] [Related]
37. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis.
Lee SH; Hwang HK; Kang CM; Lee WJ
Integr Cancer Ther; 2019; 18():1534735418816825. PubMed ID: 30501431
[TBL] [Abstract][Full Text] [Related]
38. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Rivero-Soto RJ; Yu J; Javed AA; Burkhart RA; Rinkes IHMB; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Jun; 269(6):1154-1162. PubMed ID: 31082915
[TBL] [Abstract][Full Text] [Related]
39. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
40. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.
Xia T; Xu P; Mou Y; Zhang X; Song S; Zhou Y; Lu C; Zhu Q; Xu Y; Jin W; Wang Y
World J Surg Oncol; 2023 Jun; 21(1):191. PubMed ID: 37349737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
